Medicis Announces New Patents for SOLODYN(R) 90mg

SCOTTSDALE, Ariz., May 26, 2009 (GLOBE NEWSWIRE) -- Medicis (NYSE:MRX) today announced that the United States Patent and Trademark Office (USPTO) has advised the Company that U.S. Patent No. 7,541,347 directed to the use of SOLODYN(R) in 90mg tablet form will issue on June 2, 2009, and that U.S. Patent No. 7,544,373 directed to SOLODYN(R) in 90mg tablet form will issue on June 9, 2009. The new patents include subject matter covering methods of using the 90mg controlled-release oral dosage form of minocycline to treat acne and the composition of the 90mg dosage form. Both patents will expire in 2027. For the week ending May 8, 2009, the 90mg strength represented over 62% of total SOLODYN(R) prescriptions.(1)